澳大利亚HIV相关伯基特淋巴瘤与弥漫大B细胞淋巴瘤的治疗结局:澳大利亚淋巴瘤联盟报告
分析2009—2019年澳大利亚44例HIV相关伯基特淋巴瘤(HIV-BL)和弥漫大B细胞淋巴瘤(HIV-DLBCL)患者,多数CD4计数充足且HIV病毒载量<50拷贝/mL,超过80%接受治愈性化疗、利妥昔单抗及同步抗逆转录病毒治疗(ART)。HIV-BL组2年无进展生存(PFS)和总生存(OS)均为67%,HIV-DLBCL组分别为77%和81%,治疗相关死亡5%。
要点
- HIV-BL常用R-CODOX-M/IVAC或R-Hyper-CVAD(55%),HIV-DLBCL常用CHOP(58%),45%接受更强方案。
- 接受治愈性治疗者93%完成既定疗程,治疗相关死亡5%。
- 治疗结束6个月后83%患者CD4计数>0.2×10^9/L。
核心结论
- 当前澳大利亚实践倾向于将HIV-BL和HIV-DLBCL与HIV阴性人群类似治疗并使用同步ART,结局与HIV阴性人群相当。
研究设计与样本
- 回顾性分析2009—2019年澳大利亚44例HIV相关伯基特淋巴瘤(HIV-BL)和弥漫大B细胞淋巴瘤(HIV-DLBCL)患者,处于ART和利妥昔单抗时代。
主要发现
- 诊断HIV-NHL时,多数就诊患者CD4计数充足且HIV病毒载量<50拷贝/mL。
- 超过80%患者接受治愈性化疗、利妥昔单抗及化疗同步ART(免疫治疗)。
- HIV-BL最常用R-CODOX-M/IVAC或R-Hyper-CVAD(55%);HIV-DLBCL最常用CHOP(58%),但45%接受更强化疗方案。
- 接受治愈性治疗者93%完成既定疗程;治疗相关死亡5%;治疗结束6个月后83%患者CD4计数>0.2×10^9/L。
- HIV-BL组2年PFS和OS均为67%;HIV-DLBCL组2年PFS为77%、OS为81%。
关键数值与推荐
- HIV-BL组2年PFS 67%、OS 67%;HIV-DLBCL组2年PFS 77%、OS 81%。
- 治疗相关死亡5%;完成既定疗程93%;治疗结束6个月后CD4>0.2×10^9/L者83%。
临床怎么用
- 当前澳大利亚实践倾向于对HIV-BL和HIV-DLBCL采用与HIV阴性人群类似的治疗,并使用同步ART。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antiretroviral therapy (ART) has improved outcomes for human immunodeficiency virus-associated non-Hodgkin lymphoma (HIV-NHL). This is an analysis of 44 patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated in Australia over a 10-year period (2009-2019) during the ART and rituximab era. At HIV-NHL diagnosis, the majority of presenting patients had adequate CD4 counts and undetectable HIV viral load <50 copies/mL. More than 80% of patients received chemotherapy with curative intent, rituximab, and concurrent ART with chemotherapy (immunotherapy). R-CODOX-M/IVAC or R-Hyper-CVAD (55%) were most commonly used in HIV-BL. CHOP (58%) was the most commonly used chemotherapy backbone for HIV-DLBCL, although 45% of patients received more intense chemotherapy regimens. Overall, 93% of patients who received curative therapy completed their intended course. The 2-year progression-free survival (PFS) and overall survival (OS) for the HIV-BL cohort was 67% and 67% respectively. The 2-year PFS and OS for the HIV-DLBCL cohort was 77% and 81% respectively. Treatment related mortality was 5%. In all, 83% of patients achieved a CD4 count of >0.2 ×109 /L 6 months after the end of treatment. Current Australian practice favours the treatment of HIV-BL and HIV-DLBCL similarly to the HIV-negative population with the use of concurrent ART, achieving outcomes comparable to the HIV-negative population.
引用
- Lim KJC, Di Ciaccio P, Polizzotto MN, et al. Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. Br J Haematol. 2023. PMID: 36866733. doi:10.1111/bjh.18704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。